

Official Journal

of the European Communities

ISSN 0378-6978

L 317

Volume 24

6 November 1981

English edition

Legislation

Contents

I *Acts whose publication is obligatory*

.....

II *Acts whose publication is not obligatory*

Council

81/851/EEC:

- ★ **Council Directive of 28 September 1981 on the approximation of the laws of the Member States relating to veterinary medicinal products** 1

81/852/EEC:

- ★ **Council Directive of 28 September 1981 on the approximation of the laws of the Member States relating to analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products** . 16

II

(Acts whose publication is not obligatory)

COUNCIL

COUNCIL DIRECTIVE

of 28 September 1981

on the approximation of the laws of the Member States relating to veterinary medicinal products

(81/851/EEC)

THE COUNCIL OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof,

Having regard to the proposal from the Commission ⁽¹⁾,

Having regard to the opinion of the European Parliament ⁽²⁾,

Having regard to the opinion of the Economic and Social Committee ⁽³⁾,

Whereas the primary purpose of any rules for the production and distribution of veterinary medicinal products must be the safeguarding of public health;

Whereas, however, this objective must be achieved by means which will not hinder the development of industry and trade in medicinal products within the Community;

Whereas, in so far as the Member States already have certain provisions laid down by law, regulation or administrative action governing veterinary medicinal products, such provisions differ in essential principles; whereas this results in the hindering of trade in medicinal products within the Community, thereby directly affecting the establishment and functioning of the common market;

Whereas such hindrances must, accordingly, be removed; whereas this entails approximation of the relevant provisions;

Whereas the provisions of this Directive which concern veterinary medicinal products are, although appropriate, not adequate for veterinary medicinal products used to confer active immunity, to diagnose the state of immunity and to confer passive immunity or for medicinal products based on radioactive isotopes; whereas it is therefore advisable not to prescribe their application to such products for the present;

Whereas medicated feedingstuffs do not come within the scope of this Directive; whereas, however, it is necessary, for both public health and economic reasons, to prohibit the use of unauthorized medicinal products in the manufacture of medicated feedingstuffs;

Whereas marketing authorization shall be refused where a medicinal product lacks therapeutic effect or where there is insufficient proof of such effect; whereas the concept of therapeutic effect must be understood as being the effect promised by the manufacturers;

Whereas such authorization shall also be refused where the withdrawal period indicated is not long enough to eliminate health hazards arising from residues;

⁽¹⁾ OJ No C 152, 5. 7. 1976, p. 1.

⁽²⁾ OJ No C 293, 13. 12. 1976, p. 64.

⁽³⁾ OJ No C 299, 18. 12. 1976, p. 12.

Whereas, in order gradually to achieve freedom of movement of veterinary medicinal products, the granting of marketing authorizations in several Member States for the same medicinal product should be made easier;

Whereas, for this purpose, a Committee for Veterinary Medicinal Products, composed of representatives of the Member States and of the Commission, should be set up and should be responsible for giving an opinion on whether a particular veterinary medicinal product complies with the requirements set out in this Directive;

Whereas this Directive is only one stage in the achievement of the aim of freedom of movement of veterinary medicinal products; whereas, for this purpose, new measures will prove necessary, in the light of experience gained — especially within the said Committee — for the removal of the remaining barriers to freedom of movement;

Whereas, in order to facilitate the movement of veterinary medicinal products and to prevent the checks carried out in one Member State from being repeated in another, minimum requirements for manufacture and imports from third countries and the grant of authorization relating thereto, should be applied to veterinary medicinal products, as specified in Council Directive 75/319/EEC of 20 May 1975 on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products ⁽¹⁾,

HAS ADOPTED THIS DIRECTIVE:

CHAPTER I

Definitions and scope

Article 1

1. The definitions laid down in Article 1 of Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products ⁽²⁾ shall apply to this Directive.

2. For the purposes of this Directive, the following definitions shall apply:

- 'veterinary medicinal product' shall mean any medicinal product intended for animals,

- 'ready-made veterinary medicinal product' shall mean any veterinary medicinal product prepared in advance which does not comply with the definition of proprietary medicinal products and which is marketed in a pharmaceutical form which may be used without further processing,

- 'pre-mix for medicated feedingstuffs' shall mean any veterinary medicinal product prepared in advance with a view to the subsequent manufacture of medicated feedingstuffs,

- 'medicated feedingstuffs' shall mean any mixture of a veterinary medicinal product or products and feed or feeds which is ready prepared for marketing and intended to be fed to animals without further processing, because of its curative or preventive properties or other properties as a medicinal product covered by Article 1 (2) of Directive 65/65/EEC.

3. Until Community rules are adopted for medicated feedingstuffs, Member States may lay down that this term shall include semi-finished products which are manufactured from a pre-mix for medicated feedingstuffs for which an authorization pursuant to Article 4 of this Directive has been issued and feedingstuffs, where such semi-finished products are intended to be processed by further mixing with feedingstuffs to become medicated feedingstuffs ready for use. Member States shall ensure that such semi-finished products are subject to the control of the competent authorities and that they are used exclusively for the manufacture of medicated feedingstuffs under the conditions which governed the marketing authorization for the pre-mix for medicated feedingstuffs.

4. Additives covered by Council Directive 70/524/EEC of 23 November 1970 concerning additives in feedingstuffs ⁽³⁾, as subsequently amended, where they are incorporated in animal feedingstuffs and supplementary animal feedingstuffs in accordance with that Directive, shall not be considered as veterinary medicinal products for the purposes of this Directive.

5. Member States shall take any necessary steps to ensure that antibiotics and hormone substances which may be used for the preparation of veterinary medicinal products are made available to only

⁽¹⁾ OJ No L 147, 9. 6. 1975, p. 13.

⁽²⁾ OJ No 22, 9. 12. 1965, p. 369/65.

⁽³⁾ OJ No L 270, 14. 12. 1970, p. 1.

natural or legal persons duly authorized to be in possession of them under national laws.

Article 2

1. The provisions of this Directive shall apply to veterinary medicinal products offered for sale *inter alia* in the form of proprietary medicinal products, ready-made veterinary medicinal products or pre-mixes for medicated feedingstuffs.

2. The provisions of this Directive shall not apply to:

- medicated feedingstuffs,
- veterinary medicinal products used in order to produce active immunity, diagnose the state of immunity and produce passive immunity,
- veterinary medicinal products based on radioactive isotopes,
- veterinary medicinal products not prepared in advance and intended for one particular animal or a small number of animals,
- homeopathic medicinal products.

3. However, medicated feedingstuffs may be prepared only from pre-mixes which have been authorized under this Directive. Within two years of the notification of this Directive, the Council shall, on the basis of a Commission report accompanied if necessary by appropriate proposals, deliberate on a list of pharmacological molecules which may be used for preparing pre-mixes and on the procedure for drawing up this list.

Article 3

Member States may permit exemptions from the provisions of Article 4 (1) on their territory in respect of veterinary medicinal products intended solely for aquarium fish, cage birds, homing pigeons, terrarium animals and small rodents, provided that such products do not contain substances the use of which requires veterinary control and that all possible measures have been taken to prevent unauthorized use of the products for other animals.

CHAPTER II

Application for marketing authorization for veterinary medicinal products

Article 4

1. No veterinary medicinal product may be marketed in a Member State unless authorization has previously been issued by the competent authority in that Member State.

2. No veterinary medicinal product may be administered to animals unless the authorization referred to above has been issued, except for tests of veterinary medicinal products referred to in point 10 of Article 5.

Article 5

For the purpose of obtaining the marketing authorization provided for in Article 4, the person responsible for marketing shall lodge an application with the competent authority of the Member State.

The following particulars and documents shall be appended to the application:

1. name or corporate name and permanent address or registered place of business of the person responsible for marketing and of the manufacturer, if different;
2. name of the veterinary medicinal product (brand name, non-proprietary name, with or without a trade-mark or name of the manufacturer; scientific name of formula, with or without a trade-mark or name of the manufacturer);
3. qualitative and quantitative particulars of all the constituents of the veterinary medicinal product, using the usual terminology but not empirical chemical formulae and giving the international non-proprietary name recommended by the World Health Organization, if such a name exists;
4. brief description of the method of preparation;
5. therapeutic indications, contra-indications and side-effects;
6. dosage for the various species of animal for which the veterinary medicinal product is

intended, its pharmaceutical form, method and route of administration and proposed shelf life if less than three years;

7. reasons for the precautionary and safety measures to be taken when using the veterinary medicinal product, if applicable;
 8. indication of the withdrawal period necessary between the last administration of the veterinary medicinal product to animals under normal conditions of use and the production of foodstuffs from such animals in order to ensure that such foodstuffs do not contain any residues which might constitute a health hazard to the consumer;
 9. description of the control testing methods employed by the manufacturer (qualitative and quantitative analysis of the constituents and the finished product, specific tests, e.g. sterility tests, tests for the presence of pyrogens, for the presence of heavy metals, stability tests, biological and toxicity tests, tests on intermediate products);
 10. results of:
 - physico-chemical, biological or microbiological tests,
 - toxicological and pharmacological tests,
 - clinical trials.
- (ii) a new veterinary medicinal product, in which the active ingredients are identical to those of a known medicinal product with an established use;
- (iii) a new veterinary medicinal product containing only known constituents that have already been used together in comparable proportions in adequately tested medicinal products with an established use;
- (b) in the case of a new veterinary medicinal product containing known constituents not hitherto used together for therapeutic purposes, references to published data may be substituted for the tests on such constituents;
11. one or more specimens or mock-ups of the sales presentation of the veterinary medicinal product together with a package insert where a package insert is required;
 12. a document showing that the manufacturer is authorized in his own country to produce veterinary medicinal products;
 13. any marketing authorization for the relevant veterinary medicinal product which may have been obtained in another Member State or in a third country.

The results of the toxicological and pharmacological tests must relate more particularly to the metabolism of the active ingredients in the animal and as far as possible to the mode and duration of their elimination, if such data are important for the purpose of checking the indicated withdrawal period.

However,

- (a) a copy of the published references relating to the toxicological and pharmacological tests and clinical trials and the data concerning the withdrawal period may be substituted for the relevant test results in the case of:
 - (i) a veterinary medicinal product with an established use, which has been adequately tested on animals so that its effects, including side-effects, are already known and are included in the published references;

Article 6

Member States shall make all necessary arrangements to ensure that the documents and particulars listed in points 8, 9 and 10 of the second paragraph of Article 5 are drafted by experts with the requisite technical or professional qualifications before being submitted to the competent authorities.

These documents and particulars shall be signed by the experts in question.

Article 7

According to their particular qualifications, the role of the experts shall be:

1. to carry out such work as falls within their particular discipline (analysis, pharmacology and similar experimental sciences, clinical trials) and to describe objectively the results obtained in both quantitative and qualitative terms;

2. to describe their findings in accordance with Council Directive 81/852/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products⁽¹⁾, and in particular to state:

(a) in the case of analysts, whether the product conforms with the stated composition, providing any reasons for the control testing methods which the manufacturer is to use;

(b) in the case of pharmacologists and appropriately qualified specialists:

— the toxicity of the product and the pharmacological properties observed,

— whether, after administration of the veterinary medicinal product under normal conditions of use and observance of the recommended withdrawal period, foodstuffs obtained from the treated animals contain residues which might constitute a health hazard to the consumer;

(c) in the case of clinicians, whether they have found in animals treated with the product effects corresponding to the information furnished by the manufacturer pursuant to Article 5, whether the product is well tolerated, what dosage they recommend and what are the contra-indications and side-effects, if any;

3. to give reasons for the use of the references to published data referred to in point 10 (a) and (b) of the second paragraph of Article 5, according to the conditions laid down by Council Directive 81/852/EEC.

The experts' detailed reports shall form part of the documentation which the applicant shall lodge with the competent authorities.

CHAPTER III

Examination of applications for authorization — Authorization — Renewal of authorization

Article 8

Member States shall take all appropriate measures to ensure that the procedure for granting marketing

authorization is completed within 120 days after the date of submission of the application.

In exceptional cases this time limit may be extended for a further 90 days. The applicant shall be notified of such extension before the expiry of the initial time limit.

Article 9

In order to examine the application submitted pursuant to Article 4, the competent authorities of the Member States:

1. shall check that the documentation submitted in support of the application complies with Article 5 and, on the basis of the reports drawn up by the experts pursuant to Article 7, ascertain whether the conditions for the issue of the marketing authorization have been fulfilled;
2. may submit the medicinal product for testing by a State laboratory or a laboratory designated for this purpose, in order to ensure that the control testing methods employed by the manufacturer and described in the application documents, in accordance with point 9 of the second paragraph of Article 5, are satisfactory;
3. may, where appropriate, require the applicant to provide further information as regards the items listed in Article 5. Where the competent authorities take this course of action, the time limits specified in Article 8 shall be suspended until the further data required have been provided. Similarly, these time limits shall be suspended for any period which the applicant may be given to provide oral or written explanations.

Article 10

Member States shall take all appropriate measures to ensure that:

1. the competent authorities ascertain that the manufacturers and importers of veterinary medicinal products from third countries are able to manufacture them in compliance with the details supplied pursuant to point 4 of the second paragraph of Article 5 and/or to carry out control tests in accordance with the methods described in the application documents under point 9 of the second paragraph of Article 5;
2. the competent authorities may authorize manufacturers and importers of veterinary medicinal products from third countries, where circum-

⁽¹⁾ See page 16 of this Official Journal.

stances so justify, to have certain stages of manufacture and/or certain of the control tests referred to in paragraph 1 carried out by third parties; in such cases checks by the competent authorities shall also be carried out in the establishments concerned.

Article 11

The authorization provided for in Article 4 shall be withheld if examination of the documents and particulars listed in Article 5 establishes that:

1. the veterinary medical product is harmful under the conditions of use stated at the time of application for authorization, has no therapeutic effect or the applicant has not provided sufficient proof of such effect as regards the species of animal which is to be treated, or its qualitative or quantitative composition is not as stated;
2. the withdrawal period recommended by the applicant is not long enough to ensure that foodstuffs obtained from the treated animal do not contain residues which might constitute a health hazard to the consumer, or is insufficiently substantiated;
3. the veterinary medicinal product is offered for sale for a use prohibited under other Community provisions. However, pending Community rules, the competent authorities may refuse to grant authorization for a veterinary medicinal product where such action is necessary for the protection of public health, consumer or animal health.

Authorization shall also be withheld if the application documents submitted to the competent authorities do not comply with Articles 5, 6 and 7.

Article 12

The authorization provided for in Article 4 may require the person responsible for marketing to indicate on the container and/or the outer wrapping and the package insert, where the latter is required, other particulars essential for safety or health protection, including any special precautions relating to use and any other warnings resulting from the clinical and pharmacological trials prescribed in point 10 of Article 5 or from experience gained during the use of the veterinary medicinal product once it has been marketed.

The authorization may also require the inclusion of a tracer substance in the veterinary medicinal product.

Article 13

The granting of authorization shall not diminish the general legal liability of the manufacturer and, where appropriate, of the person responsible for marketing.

Article 14

The person responsible for marketing shall modify the control test method provided for in point 9 of Article 5 in accordance with technological and scientific progress, if such modification is needed to enable the veterinary medicinal product to be controlled with a greater degree of security.

The person responsible for marketing shall forthwith inform the competent authorities of any new information which might entail amendment of the particulars and documents referred to in Article 5 or further examination and, in particular, of any prohibition or restriction imposed by the competent authorities of the States in which the veterinary medicinal product is marketed.

The person responsible for marketing shall immediately inform the competent authorities, with a view to authorization, of any alteration he proposes to make to the particulars and documents referred to in Article 5.

Article 15

Authorization shall be valid for five years and shall be renewable for five-year periods, on application by the holder at least three months before the date of expiry.

CHAPTER IV

Committee for Veterinary Medicinal Products

Article 16

1. In order to facilitate the adoption of a common position by the Member States with regard to marketing authorizations, a Committee for Veterinary

Medicinal Products, hereinafter called 'the Committee', is hereby set up; it shall be composed of representatives of the Member States and of the Commission.

2. The Committee shall, when so requested by a Member State, examine questions relating to the implementation of Articles 11, 36 and 49, in accordance with Articles 17 to 22.

3. The Committee shall draw up its own rules of procedure.

Article 17

1. A Member State which has issued a marketing authorization shall forward a copy of the application and of the authorization, together with the particulars and documents mentioned in Article 5, to the Committee and to the competent authorities of the Member States specified, if the person responsible for marketing has requested that they be forwarded to at least five other Member States.

2. Such forwarding shall be deemed equivalent to the lodging, within the meaning of Article 5, of an application for marketing authorization with the said authorities.

3. The Committee shall forthwith inform the Member States concerned that the case has been referred to the Committee.

Article 18

1. If, within a period of 120 days after the date of forwarding of the information referred to in Article 17 (2), no objection has been notified to the Committee by the competent authorities of the Member States specified, the Committee shall formally record the fact and forthwith inform the Member States concerned.

2. Where a Member State considers that it is unable to grant marketing authorization, it shall forward its reasoned objection based on Article 11 within the said period of 120 days.

Article 19

1. In the cases referred to in Article 18 (2), the Committee shall consider the matter and shall deliver its reasoned opinion within 60 days from the expiry of the time limit laid down in Article 18.

2. The opinion of the Committee shall deal with the compliance of the veterinary medicinal product with the conditions set out in Article 11.

The Committee shall forthwith inform the Member States concerned of its opinion or, in the event of dissension, of the opinions of its members.

3. The Member States concerned shall reach a decision on the application for marketing authorization not later than 30 days after the date on which the information provided for in Article 18 (1) or paragraph 2 hereof is given. They shall forthwith inform the Committee of their decision.

Article 20

1. If several applications have been submitted in accordance with Article 5 for marketing authorization for the same veterinary medicinal product and one or more Member States have granted such authorization while one or more of the other Member States have withheld it, one of the Member States concerned may bring the matter before the Committee.

The same shall apply where one or more Member States have suspended or withdrawn marketing authorization while one or more of the other Member States have not done so.

2. The Committee shall consider the matter and shall deliver its reasoned opinion within 120 days at the latest.

3. The opinion of the Committee shall deal only with the grounds on which authorization was refused, suspended or withdrawn.

The Committee shall forthwith inform the Member States concerned of its opinion or, in the event of dissension, of the opinions of its members.

4. The Member States concerned shall give notice, within 30 days, of the action they intend to take following the Committee's opinion.

Article 21

The Committee may set itself a time limit for a fresh examination on the basis of particulars relating to the conditions laid down in Articles 11, 27 or 41 obtained in the meantime by Member States, and in particular by those which have authorized the veterinary medicinal product.

Article 22

The competent authorities of Member States may, in specific cases where the interests of the Community are involved, refer the matter to the Committee before reaching a decision on an application for marketing authorization, its suspension or withdrawal.

A Member State also may refer matters to the Committee when there are grounds for believing that a medicinal product should not be authorized for use in veterinary medicine because of its importance in human therapy.

Article 23

1. The Commission shall report to the Council annually on the operation of the procedure laid down in this Chapter and its effects on the development of intra-Community trade; it shall make its first report two years after the entry into force of this Directive.

2. In the light of experience the Commission shall, not later than four years after the entry into force of this Directive, submit to the Council a proposal containing all appropriate measures for the abolition of any remaining barriers to the free movement of veterinary medicinal products. The Council shall take a decision on the Commission proposal not later than one year after its submission.

CHAPTER V

**Manufacture of veterinary medicinal products —
Imports from third countries***Article 24*

1. Member States shall take all appropriate measures to ensure that the manufacture of veterinary medicinal products is subject to the holding of an authorization.

2. The authorization referred to in paragraph 1 shall be required both for total and partial manufacture and for the various processes of dividing up, packaging or presentation.

However, such authorization shall not be required for preparation, dividing up, changes in packaging or presentation where these processes are carried out solely for retail supply by pharmacists in dispensing pharmacies or by persons legally authorized in the Member States to carry out such processes.

3. The authorization referred to in paragraph 1 shall also be required for imports from third countries

into a Member State; this Chapter and Article 36 shall apply to such imports in the same way as to manufacture.

Article 25

In order to obtain the authorization referred to in Article 24, the applicant shall meet at least the following requirements:

- (a) he shall specify the veterinary medicinal products and pharmaceutical forms which are to be manufactured or imported and also the place where they are to be manufactured and/or controlled;
- (b) he shall have at his disposal, for the manufacture or import of the above, suitable and sufficient premises, technical equipment and control facilities complying with the legal requirements which the Member State concerned lays down as regards both manufacture and control and the storage of products, in accordance with Article 10 (1);
- (c) he shall have at his disposal the services of at least one qualified person within the meaning of Article 29.

The applicant shall provide particulars in his application to establish his compliance with the above requirements.

Article 26

1. The competent authority of the Member State shall not issue the authorization referred to in Article 24 until it has established the accuracy of the particulars supplied pursuant to Article 25 by means of an inquiry carried out by its representatives.

2. In order to ensure that the requirements referred to in Article 25 are complied with, authorization may be made conditional on the fulfilment of certain obligations imposed either when authorization is granted or at a later date.

3. The authorization shall apply only to the premises specified in the application and to the veterinary medicinal products and pharmaceutical forms specified in that application.

Article 27

The holder of an authorization referred to in Article 24 shall at least be obliged to:

- (a) have at his disposal the services of staff complying with the legal requirements existing in the Member State concerned as regards both manufacture and controls;

- (b) dispose of the authorized veterinary medicinal products only in accordance with the legislation of the Member States concerned;
- (c) give prior notice to the competent authority of any changes which he may wish to make to any of the particulars supplied pursuant to Article 25; the competent authority shall, in any event, be immediately informed if the qualified person referred to in Article 29 is replaced unexpectedly;
- (d) allow the representatives of the competent authority of the Member State concerned access to his premises at any time;
- (e) enable the qualified person referred to in Article 29 to carry out his duties, particularly by placing at his disposal all the necessary facilities.

Article 28

1. The Member States shall take all appropriate measures to ensure that the time taken for the procedure for granting the authorization referred to in Article 24 does not exceed 90 days from the day on which the competent authority receives the application.

2. If the holder of the authorization requests a change in any of the particulars referred to in Article 25 (a) and (b), the time taken for the procedure relating to this request shall not exceed 30 days. In exceptional cases, this period of time may be extended to 90 days.

3. Member States may require from the applicant further information concerning both the particulars supplied pursuant to Article 25 and the qualified person referred to in Article 29; where the competent authority concerned exercises this right, application of the time limits referred to in paragraphs 1 and 2 shall be suspended until the additional data required have been supplied.

Article 29

1. Member States shall take all appropriate measures to ensure that the holder of the authorization referred to in Article 24 has permanently and continuously at his disposal the services of at least one qualified person who fulfils the conditions laid down in Article 31 and is responsible, in particular, for carrying out the duties specified in Article 30.

2. If he personally fulfils the conditions laid down in Article 31, the holder of the authorization may himself assume the responsibility referred to in paragraph 1.

Article 30

1. Member States shall take all appropriate measures to ensure that the qualified person referred to in Article 29 is, without prejudice to his relationship with the holder of the authorization referred to in Article 24, responsible, in the context of the procedures referred to in Article 33, for ensuring that:

- (a) in the case of veterinary medicinal products manufactured within the Member State concerned, each batch of veterinary medicinal products has been manufactured and checked in compliance with the laws in force in that Member State and in accordance with the requirements of the marketing authorization;
- (b) in the case of veterinary medicinal products coming from third countries, each production batch imported has undergone in the importing country a full qualitative analysis, a quantitative analysis of at least all the active ingredients and all the other tests or checks necessary to ensure the quality of veterinary medicinal products in accordance with the requirements of the marketing authorization.

Batches of veterinary medicinal products which have undergone such controls in a Member State shall be exempt from the above controls if they are imported into another Member State, accompanied by the control reports signed by the qualified person.

A Member State may relieve the qualified person of responsibility for the controls prescribed under (b) for imported veterinary medicinal products which are to remain in that Member State, if appropriate arrangements have been made with the exporting country to ensure that these controls have been carried out in the exporting country. Where these products are imported in the packaging in which they are to be sold by retail, Member States may allow exceptions to the requirements laid down in Article 25.

2. In all cases, and particularly where the veterinary medicinal products are released for sale, the qualified person shall certify, in a register or equivalent document provided for the purpose, that each production batch satisfies the provisions of this Article; the said register or equivalent document shall be kept up to date as operations are carried out and shall remain at the disposal of the representatives of the competent authority for the period specified in the provisions of the Member State concerned and, in any event, for at least five years.

Article 31

Member States shall ensure that the qualified person referred to in Article 29 fulfils the following minimum conditions of qualification.

- (a) Possession of a diploma, certificate or other evidence of formal qualifications awarded on completion of a university course of study, or a course recognized as equivalent by the Member State concerned, extending over a period of at least four years of theoretical and practical study in one of the following scientific disciplines: pharmacy, medicine, veterinary science, chemistry, pharmaceutical chemistry and technology, biology. However:

- the minimum duration of the university course may be three and a half years where the course is followed by a period of theoretical and practical training of at least one year and includes a training period of at least six months in a pharmacy open to the public, corroborated by an examination at university level,
- where two university or recognized equivalent courses co-exist in a Member State and where one of these extends over four years and the other over three years, the diploma, certificate or other evidence of formal qualifications awarded on completion of the three-year university course or its recognized equivalent shall be considered to fulfil the condition of duration referred to in (a) in so far as the diplomas, certificates or other evidence of formal qualifications awarded on completion of both courses are recognized as equivalent by the State in question.

The course shall include theoretical and practical tuition bearing upon at least the following basic subjects:

- experimental physics,
- general and inorganic chemistry,
- organic chemistry,
- analytical chemistry,
- pharmaceutical chemistry, including analysis of medicinal products,
- general and applied biochemistry (medical),
- physiology,
- microbiology,
- pharmacology,
- pharmaceutical technology,
- toxicology,
- pharmacognosy (study of the composition and effects of the active principles of natural substances of plant and animal origin).

Tuition in these subjects should be so balanced as to enable the person concerned to fulfil the obligations specified in Article 30.

In so far as certain diplomas, certificates or other evidence of formal qualifications mentioned in (a) do not fulfil the criteria laid down above, the competent authority of the Member State shall ensure that the person concerned provides evidence that he has, in the subjects involved, the knowledge required for the manufacture and control of veterinary medicinal products.

- (b) Practical experience for at least two years, in one or more undertakings which are authorized manufacturers, in the activities of qualitative analysis of medicinal products, of quantitative analysis of active principles and of the testing and checking necessary to ensure the quality of veterinary medicinal products.

The duration of practical experience may be reduced by one year where a university course lasts for at least five years and by a year and a half where the course lasts for at least six years.

Article 32

1. A person engaging in the activities of the person referred to in Article 29 in a Member State at the time when this Directive is brought into force in that State but not complying with the provisions of Article 31 shall be eligible to continue to engage in those activities in the State concerned.

2. The holder of a diploma, certificate or other evidence of formal qualifications awarded on completion of a university course — or a course recognized as equivalent by the Member State concerned — in a scientific discipline allowing him to engage in the activities of the person referred to in Article 29 in accordance with the laws of that State may — if he began his course prior to the notification of this Directive — be considered as qualified to carry out in that State the duties of the person referred to in Article 29, provided that he has previously engaged in the following activities for at least two years before the end of the 10th year following notification of this Directive in one or more undertakings authorized pursuant to Article 24: production supervision and/or qualitative analysis, quantitative analysis of active principles, and the necessary testing and checking under the direct authority of a person as referred to in Article 29 to ensure the quality of veterinary medicinal products.

If the person concerned has acquired the practical experience referred to in the first subparagraph more

than 10 years prior to the notification of this Directive, a further one year's practical experience in accordance with the conditions referred to in the first subparagraph shall be completed by him immediately before he engages in such activities.

3. A person who, at the time this Directive is brought into force, is engaged in direct collaboration with a person referred to in Article 29 in production supervision activities and/or in qualitative analysis, quantitative analysis of active principles, and the testing and checking necessary to ensure the quality of medicinal products may, for a period of five years thereafter, be considered as qualified to take up in that State the duties of the person referred to in Article 29, provided that the Member State ensures that the person shows evidence of adequate theoretical and practical knowledge and has engaged in the activities mentioned for at least five years.

Article 33

Member States shall ensure that the obligations of qualified persons referred to in Article 29 are fulfilled, either by means of appropriate administrative measures or by making such persons subject to a professional code of conduct.

Member States may provide for the temporary suspension of such a person upon the commencement of administrative or disciplinary proceedings against him for failure to fulfil his obligations.

CHAPTER VI

Supervision and sanctions

Article 34

The competent authority of the Member State concerned shall ensure, by means of inspection, that the legal requirements relating to veterinary medicinal products are complied with.

Such inspections shall be carried out by authorized representatives of the competent authority who shall be empowered to:

1. inspect manufacturing or trading establishments and any laboratories entrusted by the holder of the authorization referred to in Article 24 (1), with the task of carrying out control tests pursuant to Article 10 point 2;
2. take samples;

3. examine any documents relating to the object of the inspection, subject to current provisions in the Member States at the time of notification of this Directive which place restrictions on these powers with regard to the description of the method of preparation.

Article 35

Member States shall take all appropriate measures to ensure that the person responsible for marketing and, where appropriate, the holder of the authorization referred to in Article 24 (1) furnish proof of the control tests carried out on the finished product and/or on the constituents and intermediate products of the manufacturing process, in accordance with the methods laid down for the purposes of marketing authorization.

Article 36

The competent authorities of the Member States shall suspend or withdraw marketing authorization when it is clear that:

1. the veterinary medicinal product proves to be harmful under the conditions of use stated at the time of application for authorization or subsequently, the veterinary medicinal product does not have any therapeutic effect or its qualitative and quantitative composition is not as stated;
2. the recommended withdrawal period is inadequate to ensure that foodstuffs obtained from the treated animal do not contain residues which might constitute a health hazard to the consumer;
3. the veterinary medicinal product is offered for sale for a use which is prohibited by other Community provisions. However, pending Community rules, the competent authorities may refuse to grant authorization for a veterinary medicinal product where such action is necessary for the protection of public, consumer or animal health;
4. the information given in the application documents pursuant to Articles 5 and 14 is incorrect;
5. the control tests referred to in Article 35 have not been carried out;
6. the obligation referred to in the second paragraph of Article 12 has not been fulfilled.

The veterinary medicinal product shall be deemed to have no therapeutic effect if it is established that it does not produce therapeutic results in the species of animal for which the treatment is intended.

Authorization may also be suspended, or withdrawn where it is established that:

- the particulars supporting the application, as provided for in Article 5, have not been amended in accordance with the first and third paragraphs of Article 14,
- any new information as referred to in the second paragraph of Article 14 has not been communicated to the competent authorities.

Article 37

1. Without prejudice to Article 36, Member States shall take all necessary measures to ensure that supply of a veterinary medicinal product is prohibited and that the medicinal product concerned is withdrawn from the market where:

- (a) it is clear that the veterinary medicinal product is harmful under the conditions of use stated at the time of the application for authorization or subsequently, pursuant to the third paragraph of Article 14;
- (b) the veterinary medicinal product has no therapeutic effect on the species of animal for which the treatment was intended;
- (c) the qualitative and quantitative composition of the veterinary medicinal product is not as stated;
- (d) the recommended withdrawal period is inadequate to ensure that foodstuffs obtained from the treated animal do not contain residues which might constitute a health hazard to the consumer;
- (e) the control tests referred to in Article 35 have not been carried out, or any other requirement or obligation relating to the grant of the authorization referred to in Article 24 (1) has not been complied with.

2. The competent authority may confine the prohibition on supply and withdrawal from the market solely to the contested production batches.

Article 38

1. The competent authority of a Member State shall suspend or withdraw the authorization referred to in Article 24 for a category of preparations or for all preparations if any of the requirements laid down for obtaining this authorization is no longer met.

2. The competent authority of a Member State may, in addition to the measures provided for in Article 37, either suspend manufacture or imports of veterinary medicinal products from third countries or suspend or withdraw the authorization referred to in Article 24 for a category of preparations or for all preparations in the event of non-compliance with the provisions regarding manufacture or imports from third countries.

Article 39

Member States shall take all appropriate measures to ensure that the competent authorities concerned communicate to each other such information as is appropriate to secure compliance with the requirements for the authorization referred to in Article 24 (1) or for marketing authorization.

Article 40

All decisions taken pursuant to Articles 11, 36, 37 and 38, all negative decisions taken pursuant to Article 10 point 2 and Article 19 (3) of this Directive and all decisions to withhold authorization to manufacture or to import from third countries or to suspend or withdraw manufacturing authorization shall state in detail the reasons on which they are based. Such decisions shall be notified to the party concerned who shall at the same time be informed of the remedies available to him under current legislation and the time allowed for seeking such remedies.

Marketing authorizations and revocations of such authorizations shall be published by each Member State in its official gazette.

Article 41

No decision to:

- withhold, withdraw or suspend marketing authorization,
- prohibit the supply of a veterinary medicinal product or have it withdrawn from the market,
- withhold, withdraw or suspend authorization to manufacture or to import veterinary medicinal products from third countries,
- suspend manufacture of imports of veterinary medicinal products from third countries

may be taken on grounds other than those set out in this Directive.

Article 42

Each Member State shall take all appropriate measures to ensure that the Committee is informed immediately of decisions granting marketing authorization and of all decisions refusing or withdrawing marketing authorization, cancelling a decision refusing or withdrawing marketing authorization, prohibiting supply or withdrawing a product from the market, together with the reasons on which such decisions are based.

CHAPTER VII

Labelling and package inserts of veterinary medicinal products*Article 43*

The following information, which shall conform with the particulars and documents provided pursuant to Article 5 and be approved by the competent authorities, shall appear in legible characters on containers and outer packages of medicinal products:

1. name of the veterinary medicinal product, which may be a brand name or a non-proprietary name with or without a trade-mark or name of the manufacturer or a scientific name or formula with or without a trade-mark or name of the manufacturer;
2. next to the name of the veterinary medicinal product, its qualitative and quantitative composition expressed in active ingredients per dose-unit or as a percentage, according to the pharmaceutical form and, in the cases referred to in the second paragraph of Article 12, the tracer substances.

The international non-proprietary names recommended by the World Health Organization shall be used wherever they exist;
3. reference number for production identification (manufacturer's batch number);
4. marketing authorization number;
5. name or corporate name and permanent address or registered place of business of the person responsible for marketing and of the manufacturer, if different;
6. the species of animal for which the veterinary medicinal product is intended; the method and route of administration;

7. the withdrawal period, even if this is nil, in the case of veterinary medicinal products administered to animals intended for human consumption;
8. the date of expiry, if the shelf life is less than three years;
9. special storage precautions, if any;
10. particulars required to be indicated pursuant to the first paragraph of Article 12, if any;
11. the words 'For animal treatment only'.

The pharmaceutical form and the contents by weight, volume or number of dose-units need only be shown on the outer package.

The provisions of Part I, A of the Annex to Council Directive 81/852/EEC, in so far as they concern the qualitative and quantitative composition of veterinary medicinal products in respect of active ingredients, shall apply to the particulars provided for in point 2.

Article 44

As regards ampoules, the particulars listed in the first paragraph of Article 43 shall be given on the outer package. On the containers, however, only the following particulars shall be necessary:

- name of veterinary medicinal product,
- quantity of the active ingredients,
- route of administration,
- reference number for production identification (manufacturer's batch number),
- date of expiry,
- the words 'For animal treatment only'.

Article 45

As regards small single-dose containers, other than ampoules, on which it is impossible to give the particulars mentioned in Article 44, the requirements of Article 43 shall apply only to the outer package.

Article 46

Where there is no outer package, all the particulars which should feature on such package pursuant to the preceding Articles shall be shown on the container.

Article 47

The particulars mentioned in points 6, 7, 8, 9, 10 and 11 of the first paragraph of Article 43 and in the third and sixth indents of Article 44 shall appear on the outer package and on the container of the medicinal products in the language or languages of the country in which they are placed on the market.

Article 48

Member States shall take all appropriate measures to ensure that where a package insert is included with a veterinary medicinal product it relates solely to that product.

The package insert shall contain at least the following information, which shall conform with the particulars and documents provided pursuant to Article 5 and be approved by the competent authorities:

- (a) name or corporate name and permanent address or registered place of business of the person responsible for marketing and of the manufacturer, if different;
- (b) name of the veterinary medicinal product and a statement of its active ingredients expressed qualitatively and quantitatively.

The international non-proprietary names recommended by the World Health Organization shall be used wherever they exist;

- (c) the main therapeutic indications, contra-indications and side-effects in so far as these particulars are necessary for the use of the veterinary medicinal product;
- (d) the species of animal for which the veterinary medicinal product is intended, the dosage for each species, the method and route of administration and advice on correct administration, if necessary;
- (e) the withdrawal period, even if this is nil, in the case of veterinary medicinal products administered to animals intended for human consumption;
- (f) special storage precautions, if any;

- (g) particulars required to be indicated pursuant to the first paragraph of Article 12, if any.

Such particulars must appear in the language or languages of the country in which the product is marketed. The other information shall be clearly separate from the abovementioned particulars.

Member States may require a package insert to be included with veterinary medicinal products.

Article 49

Where the provisions of this Chapter are not observed and a formal notice addressed to the person concerned has been ineffectual, the competent authorities of the Member States may suspend or withdraw marketing authorization.

All decisions taken by virtue of the preceding paragraph shall state in detail the reasons on which they are based. A decision shall be notified to the party concerned, along with the remedies available to him under current legislation and the time allowed for seeking such remedies.

Article 50

The requirements of Member States concerning conditions of supply to the public, the marking of prices on medicinal products for veterinary use and industrial property rights shall not be affected by the provisions of this Chapter.

CHAPTER VIII

Implementing provisions and transitional measures*Article 51*

Member States shall bring into force the laws, regulations and administrative provisions necessary to comply with this Directive within 24 months of its notification and shall forthwith inform the Commission thereof.

Member States shall ensure that the main provisions of national law which they adopt in the field governed by this Directive are communicated to the Commission.

Article 52

1. As regards the authorizations referred to in Article 24 which are issued before the expiry of the time limit laid down in Article 51, Member States may grant an additional period of one year for the undertakings concerned to comply with the provisions of Chapter V.

2. The other provisions of this Directive shall be applied progressively, within 10 years of the notification referred to in Article 51, to veterinary medicinal products placed on the market by virtue of earlier provisions.

3. Member States shall notify the Commission, within three years following the notification of this Directive, of the number of veterinary medicinal products covered by paragraph 2 and, in each subsequent year, of the number of such products for which the marketing authorization referred to in Article 4 has not yet been issued.

Article 53

This Directive is addressed to the Member States.

Done at Brussels, 28 September 1981.

For the Council
The President
P. WALKER

COUNCIL DIRECTIVE**of 28 September 1981****on the approximation of the laws of the Member States relating to analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products****(81/852/EEC)**

THE COUNCIL OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof,

Having regard to the proposal from the Commission ⁽¹⁾,

Whereas the approximation begun by Council Directive 81/851/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to veterinary medicinal products ⁽²⁾ should continue and the principles laid down in that Directive should be implemented;

Whereas, among existing disparities, those relating to the control of veterinary medicinal products are of fundamental importance; whereas point 10 of the second paragraph of Article 5 of Directive 81/851/EEC requires that applications for authorization to place a veterinary medicinal product on the market should be accompanied by particulars and documents relating to the results of tests and trials carried out on the product concerned;

Whereas standards and protocols for the performance of tests and trials on veterinary medicinal products are an effective means of control of these products and, hence, of protecting public health and can facilitate the movement of these products by laying down uniform rules applicable to tests and trials and the compilation of dossiers;

Whereas the adoption of the same standards and protocols by all the Member States will enable the competent authorities to arrive at their decisions on the basis of uniform tests and by reference to uniform criteria and will, therefore, help to obviate differences in evaluation;

Whereas the physico-chemical, biological or microbiological tests provided for in point 10 of the

second paragraph of Article 5 of Directive 81/851/EEC are closely related to points 3, 4, 6 and 9 of the said paragraph; whereas it is necessary, therefore, to specify the data to be provided under those points;

Whereas the waiting period referred to in point 8 of the second paragraph of the said Article 5 of Directive 81/851/EEC must be determined in accordance with the results of the tests and trials provided for in point 10 thereof;

Whereas the concepts of harmfulness and therapeutic efficacy referred to in Article 11 of Directive 81/851/EEC can be examined only in relation to one another and have only a relative significance, depending on the progress of scientific knowledge and the use for which the medicinal product is intended; whereas the particulars and documents which must accompany an application for authorization to place a veterinary medicinal product on the market must demonstrate that potential hazards are outweighed by the therapeutic efficacy of the product; whereas, failing such demonstration, the application must be rejected;

Whereas it is the quality of the tests and trials which is pre-eminent; whereas the tests and trials carried out pursuant to these provisions must, therefore, be taken into consideration, irrespective of the nationality of the experts who perform them and of the country in which they are carried out,

HAS ADOPTED THIS DIRECTIVE:

Article 1

Member States shall take all appropriate measures to ensure that the particulars and documents which shall accompany applications for authorization to place a veterinary medicinal product on the market, pursuant to points 3, 4, 6, 8, 9 and 10 of the second paragraph of Article 5 of Directive 81/851/EEC, are submitted by the persons concerned in accordance with the Annex to this Directive.

Where, pursuant to point 10 (a) or (b) of the second paragraph of Article 5 of the abovementioned Direc-

⁽¹⁾ OJ No C 152, 5. 7. 1976, p. 11.

⁽²⁾ See page 1 of this Official Journal.

tive, references to published data are submitted, the provisions of this Directive shall apply in like manner.

Article 2

The Committee for Veterinary Medicinal Products referred to in Article 16 of Directive 81/851/EEC may examine any question relating to the application of this Directive.

Article 3

Member States shall bring into force the provisions necessary to comply with this Directive within

24 months following its notification and shall forthwith inform the Commission thereof.

Member States shall ensure that the texts of the main provisions of national law which they adopt in the field covered by this Directive are communicated to the Commission.

Article 4

This Directive is addressed to the Member States.

Done at Brussels, 28 September 1981.

For the Council

The President

P. WALKER

ANNEX

PART 1

ANALYTICAL (PHYSICO-CHEMICAL, BIOLOGICAL OR MICROBIOLOGICAL) TESTS OF VETERINARY MEDICINAL PRODUCTS**A. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE CONSTITUENTS**

The particulars and documents which shall accompany applications for marketing authorization pursuant to point 3 of the second paragraph of Article 5 of Directive 81/851/EEC shall be submitted in accordance with the following requirements; if any amendments are made to these requirements for reasons of scientific progress, all grounds shall be stated.

1. Qualitative particulars of all the constituents of the medicinal product means the designation or description of:

- the active ingredient(s),
- the constituent(s) of the excipients, whatever their nature or the quantity used, including colouring agents, preservatives, stabilizers, thickeners, emulsifiers, anti-agglutinating agents, flavouring and aromatic substances, propellents, etc.,
- the constituents of the pharmaceutical form intended to be ingested or otherwise administered to animals.

These particulars shall be supplemented by any relevant data concerning the container and, where appropriate, its manner of closure.

2. The usual terminology to be used in describing the constituents of proprietary medicinal products means, notwithstanding the application of the other provisions of point 3 of the second paragraph of Article 5 of Directive 81/851/EEC:

- in respect of substances which appear in the European Pharmacopoeia or, failing this, in the national pharmacopoeia of one of the Member States, the main title at the head of the monograph in question, which will be obligatory for all such substances, with a reference to the pharmacopoeia concerned,
- in respect of other substances, the international non-proprietary name recommended by the WHO, which may be accompanied by another non-proprietary name, or, failing this, the exact scientific designation; substances not having an international non-proprietary name or an exact

scientific designation shall be described by a statement indicating how and from what they were prepared, together with any other necessary relevant details,

- in respect of colouring matters, designation by the 'E' code assigned to them in Council Directive 78/25/EEC of 12 December 1977 on the approximation of the laws of the Member States relating to the colouring matters which may be added to medicinal products ⁽¹⁾, as last amended by Directive 81/464/EEC ⁽²⁾.

3. In order to give 'quantitative particulars' of the active constituents of the medicinal product, it is necessary, depending on the pharmaceutical form concerned, to specify the weight or the number of international units, either per dosage-unit or per unit of weight or volume of each active ingredient and with regard to the constituents of the excipient, the weight or the volume of each of them, with due allowance for the details provided in section B below.

This information shall be supplemented:

- in respect of proprietary medicinal products to be administered in drops, by the weight of each active ingredient contained in the number of drops corresponding to the recommended dose,
- in respect of syrups, emulsions, granule or preparations and other pharmaceutical forms to be administered in measured quantities, by the weight of each active ingredient per measured quantity.

Active ingredients present in the form of compounds or derivatives shall be described quantitatively by their total weight and, if necessary or relevant, by the weight of the active moiety or moieties of the molecule (in the case of chloramphenicol palmitate, for example, the weight of the ester and that of the corresponding chloramphenicol shall be given).

The biological units of activity of substances which have not been defined chemically, and on which there is insufficient bibliographical information, shall be expressed in such a way as to provide unambiguous information on the activity of the substances, e.g. by stating the physiological effect on which the method of determining the dose is based.

⁽¹⁾ OJ No L 11, 14. 1. 1978, p. 18.

⁽²⁾ OJ No L 183, 4. 7. 1981, p. 33.

B. DESCRIPTION OF METHOD OF PREPARATION

The 'brief description of the method of preparation' accompanying the application for marketing authorization pursuant to point 4 of the second paragraph of Article 5 of Directive 81/851/EEC shall be so drafted as to provide an adequate synopsis of the nature of the operations employed.

For this purpose, it shall include at least:

- mention of the various stages of manufacture, so that an assessment can be made of whether the processes employed in producing the pharmaceutical form might have produced an adverse change in the constituents,
- in the case of continuous manufacture, full details concerning precautions taken to ensure the homogeneity of the final product,
- the actual manufacturing formula, with the quantitative particulars of all the substances used, the quantities of excipients, however, being given in approximate terms in so far as the pharmaceutical form makes this necessary; mention shall be made of any substances which may disappear in the course of manufacture,
- a statement of the stages of manufacture at which sampling is carried out for in-process control tests, where other data in the documents supporting the application show such tests to be necessary for quality control of the proprietary medicinal product.

C. CONTROL OF STARTING MATERIALS

For the purposes of this paragraph, 'starting materials' means all the constituents of the proprietary medicinal product and, if necessary, of its container, as referred to in point A, paragraph 1.

The particulars and documents accompanying the application for marketing authorization pursuant to points 9 and 10 of the second paragraph of Article 5 of Directive 81/851/EEC must include the results of the tests relating to quality control of all the constituents used. These shall be submitted in accordance with the following provisions.

1. Starting materials listed in pharmacopoeias

The monographs of the European Pharmacopoeia shall be applicable to all substances appearing in it.

In respect of other substances, each Member State may require observance of its own national pharmacopoeia with regard to products manufactured in its territory.

Constituents fulfilling the requirements of the European Pharmacopoeia or the pharmacopoeia of one of the Member States shall be deemed to comply sufficiently with point 9 of the second paragraph of Article 5 of Directive 81/851/EEC. In this case, the description of the analytical methods may be replaced by a detailed reference to the pharmacopoeia in question.

However, where a starting material in the European Pharmacopoeia or in the pharmacopoeia of a Member State has been prepared by a method liable to leave impurities not mentioned in the pharmacopoeia monograph these impurities and their maximum tolerance levels must be declared and a suitable test method advanced.

Reference to pharmacopoeias of third countries may be permitted in cases where the substance is described neither in the European Pharmacopoeia nor in the national pharmacopoeia concerned; in that case the monograph shall be submitted, accompanied where necessary by a translation for which the applicant shall be responsible.

Colouring matters shall, in all cases, satisfy the requirements of Directive 78/25/EEC.

The routine tests to be carried out on each batch of starting materials shall be declared in an application for authorization to market. These tests must make it possible to provide evidence that each batch of starting material satisfies the quality requirements of the relevant pharmacopoeial monograph.

Should a specification contained in a monograph of the European Pharmacopoeia or in the national pharmacopoeia of a Member State be insufficient to ensure the quality of the substance, the competent authorities may request more appropriate specifications from the person responsible for placing the product on the market.

2. Starting materials not in a pharmacopoeia

Constituents which are not given in any pharmacopoeia shall be described in the form of a monograph under the following headings:

- (a) 'The name of the substance', meeting the requirements of point 2 of paragraph A, shall be supplemented by any trade or scientific synonyms;
- (b) 'The description of the substance', set down in a form similar to that used in a descriptive item in the European Pharmacopoeia, shall be accompanied by any necessary explanatory evidence, especially concerning the molecular structure where appropriate; it shall, in such cases be accompanied by a brief indication of the method of synthetic preparation. Where substances can be described only by their method of preparation, the description shall be sufficiently detailed to characterize a substance which is constant in both its composition and its effects;
- (c) 'Methods of identification' may be divided into complete techniques as used for the development of the medicinal product and tests which ought to be carried out as a routine matter.
- (d) 'Purity tests' shall be described in relation to the sum total of predictable impurities, especially those which may have a harmful effect, and, if necessary, those which, having regard to the combination of substances to which the application refers, may adversely effect the stability of the medicinal product or distort analytical results.

- (e) 'The assay technique(s)' shall be described in sufficiently precise detail to be reproducible in control tests carried out at the request of the competent authority; any special apparatus and equipment which may be used shall be described in adequate detail, possibly accompanied by a diagram. The formulae of the laboratory reagents shall, if necessary, be supplemented by a description of the method of preparation.

The standard error of the method, its reliability and the acceptability limits of the results shall be specified and, if necessary, justified in the lights of feasibility and the progress of scientific knowledge.

With regard to complex substances of plant or animal origin, a distinction shall be made between the case where multiple pharmacological effects render a chemical, physical or biological control of the principal constituents necessary, and the case of substances containing one or more groups of principals having similar activity, in respect of which an overall method of assay may be accepted.

- (f) 'Any special precautions which may be necessary during storage' of the starting material and, if necessary, its storage life shall be given.

D. CONTROL TESTS DURING MANUFACTURE

The particulars and documents which shall accompany an application for marketing authorization, pursuant to points 9 and 10 of the second paragraph of Article 5 of Directive 81/851/EEC, shall include particulars relating to the product control tests which may be carried out at an intermediate stage of the manufacturing process, with a view to ensuring the consistency of the technical characteristics and the production process.

These tests are essential to verify the conformity of the medicinal product with the formula when, exceptionally, an applicant proposes an analytical technique for testing the finished product which does not include the assay of all the active ingredients (or of all the excipient constituents which are subject to the same requirements as the active ingredients).

The same applies where quality control of the finished product depends on in-process control tests, particularly if the medicinal product is essentially defined by its method of preparation.

E. CONTROL TESTS ON THE FINISHED PRODUCT

The particulars and documents which shall accompany the application for marketing authorization pursuant to points 9 and 10 of the second paragraph of Article 5 of Directive 81/851/EEC, shall include particulars relating to control tests on the finished product. They shall be submitted in accordance with the following requirements.

1. General characteristics of the various pharmaceutical forms

Certain tests of the general characteristics of a product which can be carried out in the course of the manufacturing process shall be included among the tests on the finished product.

As a guideline, and subject to the possible requirements of the European Pharmacopoeia or the national pharmacopoeias of Member States, the general characteristics which are to be verified for various pharmaceutical forms are given in point 5.

These tests shall relate, wherever necessary, to the control of average weights and maximum deviations, to mechanical, physical or microbiological tests, organoleptic characteristics such as clarity, colour, taste, physical characteristics such as density, pH, refractive index, etc. For each of these characteristics, standards and tolerances shall be specified by the applicant in each particular case.

2. Identification and assay of active ingredient(s)

The description of the techniques for analyzing the finished product shall set out, in sufficiently precise detail, to enable them to be reproduced readily, the methods used for identification and assay of the active ingredient(s) in either a representative average sample from the production batch or a number of dosage-units considered individually.

In every case, the methods shall correspond to the state of scientific progress at the time and give details and explanations of the standard errors, the reliability of the analytical method and the maximum acceptable deviations.

In certain exceptional cases of particularly complex mixtures, where assay of active ingredients which are very numerous or present in very low amounts would necessitate an intricate investigation difficult to carry out in respect of each production batch, the assay of one or more active ingredients in the finished product may be omitted, on the express condition that such assays are made at intermediate stages in the production process. This relaxation may not be extended to the characterization of the substances concerned. This simplified technique shall then be supplemented, if possible, by a method of quantitative evaluation, enabling the competent authorities to have the conformity of the medicinal product with its formula verified after it has been placed on the market.

An assay of biological activity is obligatory when physico-chemical methods cannot provide adequate information on the quality of the product.

Where the particulars given in paragraph B show that a significant overage of an active ingredient was employed in the manufacture of the medicinal product, the descrip-

tion of the control tests on the finished product shall include, where appropriate, the chemical and even the toxico-pharmacological investigation of the changes that this substance has undergone, and possibly the characterization or assay of the degradation products.

3. Identification and assay of excipient constituents

An upper-limit test is obligatory in respect of excipient constituents which are subject to rules relating to toxic substances or which are used as preservatives; furthermore, constituents liable to affect physiological functions shall be assayed.

The method proposed for identifying colouring agents shall make it possible to check whether such agents are permitted under Directive 78/25/EEC.

In so far as is necessary, characterization tests shall be carried out on the other constituents of the excipient.

4. Safety tests

Apart from the toxico-pharmacological tests submitted with the application for marketing authorization, particulars of safety tests (abnormal toxicity) or local tolerance in animals shall be included in the analytical particulars wherever such tests shall be undertaken as a matter of routine in order to verify the quality of the medicinal product.

5. General characteristics of medicinal products to be verified systematically, depending on the pharmaceutical form of each product

The following requirements are given as an indication and without prejudice to any requirements of the European Pharmacopoeia or national pharmacopoeias of Member States.

- *Tablets and pills*: colour, weight and acceptable variations in unit weight; if necessary, disintegration time with the method used to determine this.
- *Coated tablets*: colour, disintegration time with the method used to determine this; weight of finished tablet; weight of core and acceptable variations in unit weight.
- *Capsules and gelatine capsules*: colour, disintegration time with the method used to determine this; appearance and weight of content, with acceptable variations in unit weight.
- *Enteric-coated preparations (tablets, capsules, gelatine capsules, granular preparations)*: in addition to the requirements of the particular pharmaceutical form, details of the resistance time and the disintegration time in variable conditions of acidity (at different pH levels), with the method used to determine them.
- *Preparations with special protective coating (tablets, capsules, gelatine capsules, granular preparations)*: in addition to the requirements of the particular pharmaceutical form, verification of the effectiveness of the coating for the desired purpose.
- *Preparations with gradual release of the active principle*: in addition to the requirements of the particular pharmaceutical form, requirements relating to gradual release, with the method used to determine this.
- *Cachets, packets and sachets*: nature and weight of contents and acceptable variations in unit weight.
- *Injectable preparations*: colour, volume of contents and acceptable variations of this volume; pH, clarity of solution, size limit of particulate matter in the case of suspensions; sterility tests, with description of test methods and, if necessary, a pyrogen test with description of method.
- *Ampoules with solid content*: quantity of medicinal product per ampoule and permitted variations in weight; sterility requirements and tests.
- *Ampoules to be taken orally*: colour, appearance, volume of content and acceptable variations.
- *Ointments, creams, etc.*: colour and consistency; weight and acceptable margin of variation; nature of container; in certain cases, microbiological control tests.
- *Suspensions*: colour; where settlement occurs, the ease of re-suspendability.
- *Emulsions*: colour; type; stability.
- *Suppositories, bougies and preparations for intra-uterine administration*: colour, weight and acceptable variations in unit weight; melting temperature or disintegration time and description of the method.
- *Aerosols*: description of container and valve with details of output; particle size-limit, where the product is intended to be inhaled.
- *Collyria, eye ointments, eye lotions*: colour; appearance; sterility controls, with description of the method used; where appropriate, clarity and size-limit of particulate matter in the case of suspension, pH determination.
- *Syrups, solutions, etc.*: colour, appearance.
- *Pre-mixes for medicated feedingstuffs*: in addition to the requirements specific to each pharmaceutical form, all relevant information on the characteristics of the pre-mix enabling a sufficiently homogeneous and stable medicated feedingstuff to be prepared.
- *Preparations for administration within the udder via the teat canal*: colour, consistency; weight of content and,

in the case of products presented in single injectable dose formulations, usable weight with acceptable deviation; sterility test; pH determination.

F. STABILITY TESTS

The particulars and documents which shall accompany the application for marketing authorization pursuant to points 6 and 9 of the second paragraph of Article 5 of Directive 81/851/EEC shall be submitted in accordance with the following requirements.

A description shall be given of the investigations by which the shelf life proposed by the applicant has been determined; in the case of pre-mixes for medicated feeding-stuffs, information should also be given as necessary on

the shelf life of the medicated feedingstuffs manufactured from these pre-mixes, in accordance with the recommended instructions for use.

Where a finished product is liable to give rise to toxic degradation products, the applicant shall declare these and indicate characterization or assay methods.

The conclusions shall contain the results of analyses, justifying the proposed shelf life under normal, or, where appropriate, under special storage conditions.

A study of the interaction between medicinal product and container shall be submitted wherever the risk of such interaction is regarded as possible, especially where injectable preparations or aerosols for internal use are concerned.

PART 2

TOXICOLOGICAL AND PHARMACOLOGICAL TESTS

The protection of the animal as a living creature shall be taken into account. However, it is recognized that for veterinary medicinal products a degree of toxicity and hazard for the animal are acceptable, provided that such toxicity has no consequences for man and that the treatment of the animal is justified on therapeutic and/or economic grounds.

The particulars and documents which shall accompany the application for marketing authorization pursuant to point 10 of the second paragraph of Article 5 of Directive 81/851/EEC shall be submitted in accordance with the requirements of Chapters I and II.

CHAPTER I

PERFORMANCE OF TESTS

A. INTRODUCTION

The toxicological and pharmacological tests shall show:

1. The potential toxicity of the medicinal product and any dangerous or undesirable effects which may occur under the proposed conditions of use in animals; these should be evaluated in relation to the gravity of the pathological condition concerned.
2. The pharmacological properties of the medicinal product, in both qualitative and quantitative relationship to the proposed use in animals.

3. To what extent and for how long after use of the medicinal product in animals there are residues in food products obtained from the animals, what their possible harmful effects are on man and what difficulties they create in the industrial processing of food.

All results shall be reliable and valid generally. Whenever appropriate, mathematical and statistical procedures shall be used in designing the experimental methods and in evaluating the results. Additionally, clinicians shall be given information about the therapeutic potential of the product and about the hazards connected with its use.

B. TOXICITY STUDY

1. Single-dose toxicity

Single-dose toxicity testing means a qualitative and quantitative study of the toxic reactions which may result from a single administration of the active substance or substances contained in the medicinal product, in the proportions in which they are present in the actual product.

Wherever it is considered necessary, the product in its actual pharmaceutical form shall be subjected to an acute toxicity test.

The single-dose toxicity test shall be carried out in at least two mammalian species of known strain, and at least two different routes of administration shall normally be used. The study with two mammalian species may be replaced by a study with one mammalian species and an animal species of another class for which the medicinal product is

intended. One of the routes of administration shall be identical with, or similar to, that proposed for use in the animal for which the medicinal product is intended and the other shall ensure systemic absorption of the substance. The study shall be carried out on equal numbers of male and female animals.

This study shall describe the symptoms observed, including local reactions. The LD₅₀ value with its confidence limits (95 %) shall, where possible, be noted. The period during which the test animals are observed shall be fixed by the investigator and shall not be less than one week.

In the case of active substances in combination, the study shall be carried out in such a way as to check whether or not potentiation or novel toxic effects occur.

2. Repeated-dose toxicity

Repeated-dose toxicity tests are intended to reveal any physiological and/or pathological changes induced by repeated administration of the active substance or combination of active substances under examination, and to determine how these changes are related to dosage.

Generally, it is desirable that at least one test be performed, the duration of which depends on the conditions of clinical use; its purpose is to determine by experiment the non-toxic dose range of the product examined during the trial. The investigator shall give reasons for the extent and duration of the trials and the dosages chosen.

If, however, having regard to, in particular, the directions for use of the medicinal product, the investigator responsible sees fit not to carry out this examination, he shall give adequate reasons for his decision.

Repeated-dose toxicity tests shall be carried out on two species of mammals, one of which shall be a non-rodent. The study with two mammalian species may be replaced by a study with one mammalian species and another animal species for which the medicinal product is intended. The choice of the route(s) of administration shall take account of the routes for therapeutic use and the likelihood of systemic absorption. The method and frequency of administration and the length of the trials shall be clearly stated.

The maximum dose should be selected so as to bring harmful effects to light. The lower doses will then enable the animal's tolerance of the new product to be determined.

Evaluation of the toxic effects shall be based on observation of behaviour, growth, haematology and physiological tests, especially those relating to the excretory organs, and also possibly on autopsy reports and accompanying histologi-

cal data. The choice and range of each group of tests depends on the species of animal used and the state of scientific knowledge at the time.

In the case of new combinations of known substances which have been investigated in accordance with the provisions of this Directive, the repeated-dose tests may, except where toxicity tests have demonstrated potentiation or novel toxic effects, be suitably modified by the investigator, who shall submit his reasons for such modifications. Substances which have been shown to be safe by wide usage over at least three years in clinical treatment of human beings or animals, and by the result of controlled trials shall be regarded as known substances which have already been investigated in accordance with these standards and protocols.

3. Tolerance in the target species of animal

The purpose of this study, which shall be carried out with all animal species for which the medicinal product is intended, is to carry out in all such animal species local and general tolerance trials designed to establish a tolerated dosage wide enough to allow an adequate safety margin and the clinical symptoms of intolerance using the recommended route or routes, in so far as this may be achieved by increasing the therapeutic dose. The report on the trials shall contain as many details as possible of the expected pharmacological effects and the adverse side-effects; the latter shall be assessed with due regard to the fact that the experimental animals may be of very high value.

The medicinal product shall be administered via the routes most likely to produce the appearance of the pharmacological effects sought.

Where the trials are carried out with animals of high unit price, the sequential method described in the Appendix hereto may be used.

4. Foetal toxicity

This investigation comprises an examination of the toxic and abortifacient effects observed in the conceived issue when the medicinal product under investigation is also intended to be administered to the female during pregnancy. If, during studies on the effects of residues, signs of foetal toxicity are observed, or if other observations made independently of such studies give rise to doubt in this respect, trials with the intended species of animal may be required. These may be carried out as part of the clinical trials.

5. Examination of reproductive function

If the results of the other tests reveal anything suggesting impairment of male or female reproductive function or

harmful effects on progeny, the reproductive function shall be investigated by appropriate tests.

An excipient used for the first time in the pharmaceutical field shall be treated like an active ingredient.

C. STUDY OF PHARMACOLOGICAL PROPERTIES

1. Pharmacodynamics

Pharmacodynamics means the study of the variations caused by the medicinal product in the functions of the organs, whether these functions are normal or experimentally modified.

This study shall follow two distinct lines of approach.

First, the actions on which the recommended application in practice is based shall be adequately described. The results shall be expressed in quantitative terms (using, for example, dose-effect curves, time-effect curves, etc.) and, wherever possible, in comparison with a substance the activity of which is well known. Where a higher therapeutic potency is being claimed for a substance, the difference shall be demonstrated and shown to be statistically significant.

Secondly, the investigator shall give a general pharmacological assessment of the substance, with special reference to the possibility of side-effects. In general, the main functions should be investigated. This investigation shall be intensified as the doses liable to produce side-effects approach those producing the therapeutic effects for which the substance is being proposed.

The experimental techniques, unless they are standard procedures, shall be described in such detail as to allow them to be reproduced, and the investigator shall establish their validity. The experimental results shall be set out clearly and, for certain types of tests, their statistical significance quoted.

Unless good reasons are given to the contrary, any quantitative modification of responses resulting from repeated administration of the substance shall also be investigated.

Medicinal combinations may be prompted either on pharmacological grounds or by clinical indications. In the first case, the pharmacodynamic study shall demonstrate those interactions which might make the combination itself of value in clinical use. In the second case, where scientific justification for the medicinal combination is sought through clinical experimentation, the investigation shall determine whether the effects expected from the combination can be demonstrated in animals and, at least, the

importance of any side-effects shall be checked. If a combination includes a novel active substance, the latter shall have been previously studied in depth.

2. Pharmacokinetics

Pharmacokinetics means the study of the life of the substances within the body, and covers the study of the absorption, distribution, biotransformation (or metabolism) and elimination of the products.

The study of these different phases may be carried out both by means of physical, chemical or biological methods and by observation of the actual pharmacodynamic activity of the medicinal product.

Information on distribution and elimination is required in respect of chemotherapeutic substances (antibiotics, etc.) and substances the use of which depends on their non-pharmacodynamic effects and in all cases where it is essential to determine the dosage for animals or to determine residues in foodstuffs.

In the case of new combinations of known substances which have been investigated in accordance with the provisions of this Directive, pharmacokinetic studies are not required if the toxicity tests and clinical trials justify their omission. The same applies to substances which have been shown by controlled trials to be efficacious and safe by wide usage over a period of at least three years in the clinical treatment of human beings or animals.

D. STUDY OF RESIDUES

For the purposes of this Directive, 'residues' means all active ingredients or metabolites thereof which remain in meat or other foodstuffs produced from the animal to which the medicinal product in question has been administered.

The purpose of studying residues is to determine whether and, if so, under what conditions and to what extent residues persist in foodstuffs produced from treated animals and to ascertain the withdrawal periods to be adhered to in order to obviate any hazard to human health and/or difficulties in the industrial processing of foodstuffs.

Assessment of the hazard due to residues entails establishing whether residues are present in the animals treated under recommended conditions of use and investigating the effects of those residues.

1. Determination of residues

The determination of residues shall be carried out with regard to, in particular, the results of the pharmacokinetic tests. At varying times after the test animal has received the final dose of the medicinal product, the quantities of residues present shall be determined by appropriate physical, chemical or biological methods; the technical procedures

and the reliability and sensitivity of the methods employed shall be specified. If of practical value, the results shall be checked as far as possible, at least by examining the sick animals for which the medicinal product is recommended.

Checking procedures shall be proposed which can be carried out in the course of a routine examination and which have a level of sensitivity such as to enable residue concentrations likely to affect health in animal-based foodstuffs to be determined with certainty.

2. Investigation of the effects of residues

(a) Toxicity of orally administered residues

Toxicity studies to determine the safety of orally administered residues shall be performed differently according to whether it is a medicinal product which is eliminated without transformation or one which is metabolized. In the first case, the investigator may work directly with the medicinal product. In the second case, he shall work on the principal metabolites chiefly found in foodstuffs. If the metabolites cannot be isolated or synthesized, the toxicity study shall be carried out by a different method; in such cases recourse may be had to a study of 'relay' toxicity.

The trials shall be carried out, using the oral route, on two mammalian species, one of which shall be a non-rodent and shall normally last from three to six months. If the medicinal product or metabolite is worked on directly, the doses shall be fixed with due regard to the residues actually present and shall be so selected that the highest dose causes harmful effects to appear as far as possible, while the lower doses then enable the limit of tolerance in animals to be found. If the study of 'relay toxicity' is adopted, the upward gradation of the doses will be limited by the quantity of residues actually present.

Evaluation of the toxic effects shall be based on observation of behaviour, growth, haematology and physiological tests, especially those relating to the excretory organs, as well as on autopsy reports and accompanying histological data. The choice and range of each group of tests will depend on the species of animal used and the state of scientific knowledge at the time.

(b) Other effects of orally administered residues

Effects of residues on the reproductive functions shall be tested in rodents of both sexes.

Tests to reveal carcinogenic effects are indispensable:

1. in respect of substances having a close chemical analogy with known carcinogenic or co-carcinogenic compounds;
2. in respect of substances which have given rise to suspect signs and symptoms during the repeated-dose toxicity study;
3. when the test for mutagenic effects produces results indicating a possibility of carcinogenic effects.

Tests to reveal teratogenic effects are indispensable:

1. in respect of substances having a close chemical analogy with known teratogenic products;
2. in respect of substances which have given rise to abnormal signs and symptoms during the study of effects on the reproductive functions;
3. in respect of new molecules with a chemical structure not analogous to known products.

The study of teratogenic effects shall be carried out with at least two animal species: rabbits, using a breed sensitive to substances known to possess foetal toxicity, and rats or mice (specifying the strain). The details of the test (number of animals, doses, time at which administered and criteria for evaluation of results) depend on the state of scientific knowledge at the time when the application is lodged and the level of statistical significance which the results shall attain.

Furthermore, a study of mutagenic effects carried out by means of a test (such as the Ames test) suitable for the assessment of hazards is necessary.

A study of allergic phenomena is desirable.

(c) Difficulties affecting the industrial processing of foodstuffs

In certain cases, it may be necessary to carry out tests to determine whether residues cause difficulties affecting technological processes in industrial foodstuff processing.

3. Exceptions

Toxicity studies (a) to (c) are not required if it has been established that the medicinal product is rapidly and completely eliminated or if it is used only occasionally. In such cases, the withdrawal period shall be fixed according to the data available, so that there is no risk of danger to consumers of foodstuffs.

E. MEDICINAL PRODUCTS FOR TOPICAL USE

Where a medicinal product is intended for topical use, systemic absorption shall be investigated in the target species of animal. If it is proved that systemic absorption is negligible, the repeated-dose toxicity tests, the foetal toxicity tests and the studies of reproductive function referred to at points B.2, B.4 and B.5 may be omitted.

If the medicinal product is absorbed systemically in a significant quantity from the point of view of residues or from that of pharmacodynamics (concentration) or if, under the conditions of use laid down, oral ingestion of the medicinal product by the animal is to be expected, the medicinal product shall be investigated in accordance with the requirements of points B to D.

In all cases, tests of local tolerance after repeated administration shall be carried out and shall include histological examinations. Where a medicinal product which is not systemically absorbed may enter a food product obtained from the treated animal (intra-mammary preparations, etc.), the assay of residues in accordance with point D shall be carried out each time.

F. RESISTANCE

Data on the emergence of resistant organisms are necessary in the case of medicinal products (notably antimicrobials) used for the prevention or treatment of infectious disease in animals.

CHAPTER II**PRESENTATION OF PARTICULARS AND DOCUMENTS**

As in any scientific work, the dossier of toxicological and pharmacological tests shall include the following:

- (a) an introduction defining the subject, accompanied by any useful bibliographical references;
- (b) a detailed experimental protocol giving the reasons for any omission of certain tests listed above, a description of the methods, apparatus and materials used, details of the species, breed or strain of animals, where they were obtained, their number and the conditions under which they were housed and fed, stating *inter alia* whether they were free from specific pathogens (SPF) or traditional pathogens;

- (c) all the results obtained, whether favourable or unfavourable. The original data should be described in sufficient detail to allow the results to be critically evaluated independently of their interpretation by the author. By way of explanation and illustration, the results may be accompanied by reproductions of kymograms, photomicrographs, etc.;
- (d) a statistical analysis of the results, where such is called for by the test programme, and variance within the data;
- (e) an objective discussion of the results obtained, leading to conclusions on the toxicological and pharmacological properties of the substance, on its safety margin in the test animal and the target animal and its possible side-effects, on its fields of application, on its active dose levels and any possible incompatibilities;
- (f) information showing whether the constituents of the medicinal product are used as medicinal products in human therapy; if this is so, a report should be made on all the effects observed (including side-effects) in man and on their cause, to the extent that they may be important for the assessment of the veterinary medicinal product, where appropriate in the light of trial results or bibliographical documents; where constituents of the medicinal products are themselves not used or are no longer used as medicinal products in human therapy, the reasons should be stated;
- (g) a detailed description and a thorough discussion of the results of the study on the presence of residues in food and an assessment of the hazards which they constitute for man. Account should be taken of all the factors which may be of importance, particularly with regard to customary diet and levels of contamination by foreign matter present in the environment. In the case of each recommended use, this description shall be followed by proposals concerning the withdrawal periods which, allowing for an adequate safety margin, shall be so established as to ensure that no further residue remains in food or, if this is impossible, to ensure that any danger to man is eliminated by applying internationally recognized assessment criteria: dose devoid of effect in animals, acceptable daily dose (ADD), safety margin of 1:100 or $\leq$ 1:100 according to available information, etc.;
- (h) all information necessary to acquaint the clinician as fully as possible with the utility of the proposed product. The discussion will be supplemented by suggestions as to side-effects and possible treatment for acute toxic reactions in animals to which the product is to be administered;
- (i) a summary together with precise bibliographical references.

PART 3

CLINICAL TRIALS

The particulars and documents which shall accompany applications for marketing authorizations pursuant to point 10 of the second paragraph of Article 5 of Directive 81/851/EEC shall be submitted in accordance with the provisions of Chapters I and II below.

CHAPTER I

CONDUCT OF TRIALS

The purpose of clinical trials is to demonstrate or to ascertain the therapeutic effect of the medicinal product, to specify its indications and contra-indications according to species, age, its directions for use, any side-effects which it may have and its safety under normal condition of use.

Clinical trials shall be preceded by adequate pharmacological and toxicity tests carried out in accordance with the provisions of this Directive and, where they are practicable, by tests carried out preferably on the one or more animal species for which the medicinal product is intended. The investigator shall acquaint himself with the conclusions of these preliminary trials.

As far as possible, clinical trials shall be carried out with control animals (controlled clinical trials); if it is economically justifiable, the therapeutic effect obtained should be compared both with a placebo and with absence of treatment and/or with the effect of a medicinal product of known therapeutic value which has already been used. All the results obtained, whether positive or negative, shall be reported.

The methods used to make the diagnosis shall be specified. The results shall be set out by making use of quantitative or conventional criteria (system of crosses, etc.).

CHAPTER II

PARTICULARS AND DOCUMENTS

Particulars concerning clinical trials shall be sufficiently detailed to enable an objective judgement to be made.

1. Records of clinical observations

All the particulars shall be supplied by each of the investigators on individual record-sheets in the case of individual treatment and collective record-sheets in the case of collective treatment.

The particulars supplied shall take the following form:

(a) name, address, function and university qualifications of investigator;

(b) place and date of treatment; name and address of owner of the animals;

(c) in the case of individual treatment and collective treatment, if the latter has been given, full identification of the trial animals, names or registered numbers, species, breeds or strains, age, weight, sex (in the case of females, specify whether pregnant or in milk and, in the case of birds, in lay, etc.);

(d) method of rearing and feeding, stating the nature and quantity of any additives contained in the feed;

(e) case history (as full as possible), occurrence and course of any inter-current diseases;

(f) diagnosis and means used to make it;

(g) symptoms and severity of the disease, if possible according to conventional criteria (system of crosses, etc.);

(h) dosage of the medicinal product, method, route and frequency of administration and precautions, if any, taken during administration (duration of injection, etc.);

(i) duration of treatment and period of subsequent observation;

(j) all details concerning medicinal products (other than that being assayed) which have been administered during the period of examination, either prior to or concurrently with the test product and, in the latter case, details of the interactions observed;

(k) all results of the clinical trials (including unfavourable or negative results) with a full statement of the clinical observations and the results of the objective tests of activity (laboratory analyses, physiological tests), required to evaluate the application; the techniques used must be specified, and the significance of any variations in the results explained (for example: variance in method, variance between individuals or the effects of the medication); demonstration of the pharmacodynamic effect in animals shall not in itself suffice to justify conclusions concerning any therapeutic effect;

(l) all particulars of the observed side-effects, whether harmful or not, and of any measures taken in consequence; the cause-and-effect relationship shall be investigated if possible;

(m) effect on animals' performances (for example: egg-laying, milk production and reproductive function);

(n) a conclusion on each individual case or, where collective treatment is concerned, on each collective case.

Omission of one or more of items (a) to (n) shall be explained.

Where, in respect of particular therapeutic indications, the applicant can show that he is unable to provide comprehensive data on therapeutic effect because:

- (a) the indications for which the medicinal product in question is intended are encountered so rarely that the applicant cannot reasonably be expected to provide comprehensive evidence;
- (b) in the present state of scientific knowledge, comprehensive information cannot be provided,

the marketing authorization may be granted subject to the following conditions:

- (a) the medicinal product in question is to be supplied on veterinary prescription only and may, in certain cases, be administered only under strict veterinary supervision;
- (b) the package insert and any other information must draw the attention of the veterinary practitioner to the fact that, in certain specified respects, the particulars available concerning the medicinal product in question are as yet inadequate.

The person responsible for placing the veterinary medicinal product on the market shall make all necessary arrangements to ensure that the original documents, which formed the basis of the data supplied, are kept for at least five years as from the date of transmission of the dossier to the competent authority.

2. Summary and conclusions

The clinical observations referred to in paragraph 1 shall be summarized in a synopsis of the trials and the results thereof, indicating in particular:

- (a) the number of animals treated either individually or collectively, with a breakdown according to species, breed or strain, age and sex;
- (b) the number of animals withdrawn prematurely from the trials and the reasons for such withdrawal;
- (c) in the case of control animals, whether they have:
 - received no treatment;
 - received a placebo;
 - received another medicinal product of known effect;
- (d) the frequency of observed side-effects;
- (e) observations as to the effect on performance (for example: egg-laying, milk production and reproductive function), where the medicinal product is intended for animals in which yield is an important factor;
- (f) details concerning test animals which may be at increased risk owing to their age, their mode of rearing or feeding, or the purpose for which they are intended, or animals the physiological or pathological condition of which requires special consideration;
- (g) a statistical evaluation of the results, when this is called for by the test programme.

Finally, the investigator shall draw general conclusions from the experimental evidence, expressing his opinion on the harmlessness of the medicinal product under normal conditions of use, its therapeutic effect and any useful information relating to indications and contra-indications, dosage and average duration of treatment and, where appropriate, any interactions observed with other medicinal products or feed additives as well as any special precautions to be taken during treatment and the clinical symptoms of overdosage.

Appendix

SEQUENTIAL METHOD

This method consists of calculating a non-lethal theoretical dose for the animal concerned on the basis of the pharmacologically effective doses, determined during the experimental trials with the medicinal product, bearing in mind the maximum tolerated doses observed during the single-dose toxicity study, in accordance with point B.1. That dose is then administered to an animal which shall be watched very carefully in order that as much information as possible may be obtained regarding the effects of the medicinal product. If the animal displays no symptoms of non-tolerance, the test shall recommence with another animal, using a higher dose the strength of which is left to the investigator's discretion. If the animal easily tolerates this new dose, the test shall be continued with a further higher dose. The dose which shall not be exceeded shall be that obtaining at the point where symptoms of toxicity appear. If the animal dies, the test shall recommence with a lower dose, and so on. In every case, the aim is to determine a single dosage which enables a favourable pharmacological effect to be obtained without harming the animal.